<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762890</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0206</org_study_id>
    <nct_id>NCT02762890</nct_id>
  </id_info>
  <brief_title>Comparison of Deep Neuromuscular Block and Moderate Neuromuscular Block on Quality of Recovery in Patients Undergoing Robotic Gastrectomy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and compare the postoperative quality of recovery
      between the deep neuromuscular blockade and moderate neuromuscular blockade during robotic
      gastrectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2016</start_date>
  <completion_date type="Actual">February 27, 2017</completion_date>
  <primary_completion_date type="Actual">February 27, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative quality of recovery</measure>
    <time_frame>within 48 hours after the end of surgery.</time_frame>
    <description>The postoperative quality of recovery will be evaluated at 24 and 48 hours after the end of surgery by the investigator who are blinded to the group assignments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical condition</measure>
    <time_frame>within 48 hours after the end of surgery</time_frame>
    <description>Surgical condition will be evaluated after the end of surgery by the investigator who are blinded to the group assignments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>shoulder pain</measure>
    <time_frame>within 48 hours after the end of surgery</time_frame>
    <description>shoulder pain will be evaluated after the end of surgery by the investigator who are blinded to the group assignments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal pain</measure>
    <time_frame>within 48 hours after the end of surgery</time_frame>
    <description>abdominal pain will be evaluated after the end of surgery by the investigator who are blinded to the group assignments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nausea and vomiting</measure>
    <time_frame>within 48 hours after the end of surgery</time_frame>
    <description>nausea and vomiting will be evaluated after the end of surgery by the investigator who are blinded to the group assignments.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>General Anesthesia</condition>
  <arm_group>
    <arm_group_label>Deep neuromuscular blockade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rocuronium will be administered continuously to achieve post-tetanic count 1-2 during surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate neuromuscular blockade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium will be administered continuously to achieve Train-of-four 1-2 during surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deep neuromuscular blockade</intervention_name>
    <description>neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.</description>
    <arm_group_label>Deep neuromuscular blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moderate neuromuscular blockade</intervention_name>
    <description>neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.</description>
    <arm_group_label>Moderate neuromuscular blockade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients aged 19-80 years who are scheduled for robotic gastrectomy

        Exclusion Criteria:

          -  Neuromuscular disease

          -  History of malignant hyperthermia

          -  Significant renal or hepatic dysfunction

          -  Allergy to sugammadex or rocuronium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine Anesthesia and Pain Research Institute Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no plan to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

